Date: 9/18/2006 7:30:00 AM

    SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL) today announced that its presentation at the UBS Global Life
Sciences Conference will be webcast live on Monday, September 25, 2006, at
8:00 a.m. Eastern Time.  Vical's President and Chief Executive Officer,
Vijay B. Samant, will provide an overview of the company's technologies,
development programs, and strategic partnerships.  The audio webcast will be
available through a link in the Webcast Center at www.vical.com.  A replay
will be available beginning approximately three hours after the live
presentation.

    About Vical

    Vical researches and develops biopharmaceutical products based on its
patented DNA delivery technologies for the prevention and treatment of serious
or life-threatening diseases.  Potential applications of the company's DNA
delivery technology include DNA vaccines for infectious diseases or cancer, in
which the expressed protein is an immunogen; cancer immunotherapeutics, in
which the expressed protein is an immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an angiogenic growth factor.  The
company has developed certain infectious disease vaccines and cancer
therapeutics internally.  In addition, the company collaborates with major
pharmaceutical companies and biotechnology companies that give it access to
complementary technologies or greater resources.  These strategic partnerships
provide the company with mutually beneficial opportunities to expand its
product pipeline and serve significant unmet medical needs.  Additional
information on Vical is available at www.vical.com.

    This press release contains forward-looking statements subject to risks
and uncertainties that could cause actual results to differ materially from
those projected, including: whether any product candidates will be shown to be
safe and efficacious in clinical trials, the timing of clinical trials,
whether Vical or its collaborative partners will seek or gain approval to
market any product candidates, the dependence of the company on its
collaborative partners, and additional risks set forth in the company's
filings with the Securities and Exchange Commission.  These forward-looking
statements represent the company's judgment as of the date of this release.
The company disclaims, however, any intent or obligation to update these
forward-looking statements.



    Contacts:   Investors:                   Media:
                Alan R. Engbring             Susan Neath
                Vical Incorporated           Porter Novelli Life Sciences
                (858) 646-1127               (619) 849-6007
                Website:  www.vical.com


SOURCE  Vical Incorporated
    -0-                             09/18/2006
    /CONTACT:  Investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007, for Vical Incorporated/
    /Web site:  http://www.vical.com /
    (VICL)

CO:  Vical Incorporated
ST:  California
IN:  HEA BIO MTC
SU:  TDS CCA MAV

SF-KA
-- LAM015 --
5533 09/18/2006 07:30 EDT http://www.prnewswire.com